Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 12, Issue 3, Pages 576-592
Publisher
Informa UK Limited
Online
2015-11-04
DOI
10.1080/21645515.2015.1102809
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LBA-09 * Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab
- (2015) F. Ciardiello et al. ANNALS OF ONCOLOGY
- Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC):
- (2015) Andrew G. Hill et al. CANCER RESEARCH
- Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
- (2015) A. Bertotti et al. CLINICAL CANCER RESEARCH
- Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
- (2015) D. Juric et al. CLINICAL CANCER RESEARCH
- Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
- (2015) H. J. Jacobsen et al. CLINICAL CANCER RESEARCH
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
- (2015) C. Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
- (2015) Luigi Fattore et al. Journal of Translational Medicine
- Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
- (2015) M. W. Pedersen et al. MOLECULAR CANCER THERAPEUTICS
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Examination of HER3 targeting in cancer using monoclonal antibodies
- (2015) Nadège Gaborit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
- (2015) Maicol Mancini et al. Science Signaling
- Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
- (2015) R. Dienstmann et al. Cancer Discovery
- Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
- (2015) Maicol Mancini et al. Science Signaling
- The Potential of panHER Inhibition in Cancer
- (2015) Xiaochun Wang et al. Frontiers in Oncology
- The promise of anti-ErbB3 monoclonals as new cancer therapeutics
- (2015) Luigi Aurisicchio et al. Oncotarget
- HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
- (2015) Gaëlle Thomas et al. Oncotarget
- The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
- (2015) Hisato Kawakami et al. Oncotarget
- Regulation of ERBB3/HER3 signaling in cancer
- (2015) Kalpana Mujoo et al. Oncotarget
- Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and FoxO1 Phosphorylation
- (2015) Yassamine Lazrek et al. NEOPLASIA
- Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
- (2015) Mari Iida et al. NEOPLASIA
- Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation
- (2014) Zhen Zhao et al. CANCER BIOLOGY & THERAPY
- Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk
- (2014) S. Hu et al. CANCER RESEARCH
- Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
- (2014) Shanthi Kanthala et al. Chemical Biology & Drug Design
- Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
- (2014) K. Meetze et al. CLINICAL CANCER RESEARCH
- Are Corticosteroids Effective in All Patients With Cancer-Related Pain?
- (2014) James F. Cleary JOURNAL OF CLINICAL ONCOLOGY
- miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer
- (2014) Xin Yan et al. Molecular Cancer
- Targeting of erbB3 receptor to overcome resistance in cancer treatment
- (2014) Jian Ma et al. Molecular Cancer
- Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
- (2014) N. Jiang et al. MOLECULAR CANCER THERAPEUTICS
- ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
- (2014) L. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling
- (2014) Z Huang et al. ONCOGENE
- Application of molecular technologies for phosphoproteomic analysis of clinical samples
- (2014) M Pierobon et al. ONCOGENE
- Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies
- (2014) Jimson W. D’Souza et al. PLoS One
- Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
- (2014) J. J. Tao et al. Science Signaling
- EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo
- (2014) Gianluca Sala et al. Translational Oncology
- Oncogenic ERBB3 Mutations in Human Cancers
- (2013) Bijay S. Jaiswal et al. CANCER CELL
- Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110 Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
- (2013) J. T. Garrett et al. CANCER RESEARCH
- RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
- (2013) C. Mirschberger et al. CANCER RESEARCH
- An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
- (2013) A. P. Garner et al. CANCER RESEARCH
- Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2013) P. LoRusso et al. CLINICAL CANCER RESEARCH
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
- (2013) Jeffrey C Kang et al. mAbs
- erbB3 Is an Active Tyrosine Kinase Capable of Homo- and Heterointeractions
- (2013) M. P. Steinkamp et al. MOLECULAR AND CELLULAR BIOLOGY
- The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
- (2013) Jingcao Huang et al. Molecular Cancer
- Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models
- (2013) Y. Wu et al. MOLECULAR CANCER THERAPEUTICS
- MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
- (2013) J. B. Fitzgerald et al. MOLECULAR CANCER THERAPEUTICS
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
- (2013) D. A. Ferraro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non-Small Cell Lung Cancer
- (2013) G. V. Hegde et al. Science Translational Medicine
- Functional cooperation of miR-125a, miR-125b and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
- (2013) S Wang et al. Cell Death & Disease
- Abstract 2509: AV-203, a humanized ERBB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ERBB3 signaling in vitro and in vivo
- (2012) Sylvie Vincent et al. CANCER RESEARCH
- Abstract 2508: GE-huMab-HER3, a novel humanized, glycoengineered HER3 antibody with enhanced ADCC and superior preclinicalin vitroandin vivoefficacy
- (2012) Birgit Bossenmaier et al. CANCER RESEARCH
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner
- (2012) Malgorzata Magdalena Sak et al. CARCINOGENESIS
- Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
- (2012) J. D. Wulfkuhle et al. CLINICAL CANCER RESEARCH
- GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
- (2012) C. A. Gerdes et al. CLINICAL CANCER RESEARCH
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis
- (2012) Alberto Ocana et al. JNCI-Journal of the National Cancer Institute
- Abstract A182: U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN).
- (2012) D. J. Freeman et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines
- (2011) Edith Blackburn et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
- (2011) J S Liles et al. BRITISH JOURNAL OF CANCER
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Docetaxel combined with targeted therapies in metastatic breast cancer
- (2011) Javier Cortes et al. CANCER TREATMENT REVIEWS
- Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
- (2011) Niels Jørgen Østergaard Skartved et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes
- (2011) Steven M. Jay et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors
- (2011) Luigi Aurisicchio et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling
- (2011) G Sala et al. ONCOGENE
- A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis
- (2011) M Lindzen et al. ONCOGENE
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
- (2010) Qing Sheng et al. CANCER CELL
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
- (2010) M. W. Pedersen et al. CANCER RESEARCH
- CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
- (2010) José Baselga et al. Clinical Breast Cancer
- AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer
- (2010) D. M. Hickinson et al. CLINICAL CANCER RESEARCH
- Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments
- (2010) Fabrício F T Barros et al. HISTOPATHOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
- (2010) S Wang et al. ONCOGENE
- Roles for Growth Factors in Cancer Progression
- (2010) Esther Witsch et al. PHYSIOLOGY
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
- (2009) Olivier Rixe et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells
- (2009) M. Narayan et al. CANCER RESEARCH
- Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
- (2009) C. Desbois-Mouthon et al. CLINICAL CANCER RESEARCH
- Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
- (2009) T. Ben-Kasus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- (2009) B. Schoeberl et al. Science Signaling
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Acquired resistance to tyrosine kinase inhibitors during cancer therapy
- (2008) Jeffrey A Engelman et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- EGFR family: Structure physiology signalling and therapeutic targets†
- (2008) Antony W. Burgess GROWTH FACTORS
- Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy
- (2008) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started